Figure 3.

LYCAT knockdown inhibits NSCLC cell migration in vitro and oncogenic potential in vivo. A and C, a 3-mm scrape wound was created in confluent cultures of H2122 (A) and H23 (C) NSCLC cells stably expressing LYCAT shRNAs. Later, migration of the cells toward the scrape wound was recorded at 0 and 24 h. Scale bar, 100 μm. B and D, cell migration rates of H2122 (B) and H23 (D) LYCAT knockdown clones were assayed in transwell inserts as described under “Experimental procedures.” Scale bar, 200 μm. ***, p < 0.05 versus parental control. E and F, cell migration of CRISPR-Cas9 LYCAT gene–edited H2122 (E) and H23 (F) clones was assayed in transwell inserts as described under “Experimental procedures.” **, p < 0.01 versus parental control. Scale bar, 200 μm. G and H, cell invasion of CRISPR-Cas9 LYCAT gene–edited H2122 (G) and H23 (H) clones was assayed in transwell inserts coated with Matrigel as described under “Experimental procedures.” **, p < 0.01 versus parental control. Scale bar, 200 μm. I, the extent of apoptosis in CRISPR-Cas9 LYCAT gene–edited H2122 and H23 clones was assayed by annexin V–FITC staining as described under “Experimental procedures.” J and K, a single clone of H2122 LYCAT knockdown was subcutaneously injected into athymic nude mice. Tumor weights (J) and tumor-bearing mice (K) are displayed. *, p < 0.05 versus control. Error bars, S.E.